

Amendments to the Claims:

Please amend claims 26-28. Please add new claims 52-59. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.– 5. **(Canceled)**

6. **(Previously Presented)** The method of claim 26 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

7. **(Canceled)**

8. **(Previously Presented)** The method of claim 26 wherein the reovirus is a mammalian reovirus.

9. **(Original)** The method of claim 8 wherein the mammalian reovirus is a human reovirus.

10. **(Original)** The method of claim 9 wherein the human reovirus is a serotype 3 reovirus.

11. **(Original)** The method of claim 10 wherein the serotype 3 reovirus is a Dearing strain reovirus.

12. – 15. **(Canceled)**

16. **(Previously Presented)** The method of claim 26 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.

17. – 21. **(Canceled)**

22. **(Previously Presented)** The method of claim 26 wherein the reovirus is administered systemically.

23. – 25. **(Canceled)**

26. **(Previously Presented)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

- (a) identifying a subject including ras-activated neoplastic cells susceptible to a chemotherapeutic agent;
- (b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and
- (c) administering to the subject an effective amount of [[a]]the chemotherapeutic agent,

wherein the infection prevents the ras-activated neoplasm from developing development of drug resistance to the chemotherapeutic agent.

27. **(Currently amended)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

- ~~(a) identifying a subject including ras-activated neoplastic cells susceptible to a chemotherapeutic agent;~~
- [[b]](a) administering to a subject having a ras-activated neoplasm capable of developing drug resistance to a chemotherapeutic agent, to the subject

an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

[[ (c ) ] ] ( b ) administering to the subject an effective amount of [[ a ] ] the chemotherapeutic agent,

~~wherein the reovirus is administered prior to administration of the chemotherapeutic agent, and~~ wherein the infection prevents the ras-activated neoplasm from developing ~~development~~ of drug resistance to the chemotherapeutic agent.

28. **(Currently amended)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

(a) ~~identifying~~ determining, in a subject having a ras-activated neoplasm, if the ras activated neoplasm includes ~~including~~ ras-activated neoplastic cells ~~susceptible~~ that are refractory to a chemotherapeutic agent;

(b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

(c) administering to the subject an effective amount of [[ a ] ] the chemotherapeutic agent,

~~wherein the reovirus and the chemotherapeutic agent are administered concurrently, and~~ wherein the infection prevents the ras-activated neoplasm from developing ~~development~~ of drug resistance to the chemotherapeutic agent.

29. **(Original)** The method of claim 26 wherein the chemotherapeutic agent is cisplatin.

30. **(Previously Presented)** The method of claim 26 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.
31. **(Withdrawn)** A method of sensitizing a neoplastic cell to a chemotherapeutic agent, comprising: (a) administering to said neoplastic cell an effective amount of a virus, said virus being capable of selectively infecting neoplastic cells; and (b) administering an effective amount of the chemotherapeutic agent to said cell.
32. **(Withdrawn)** The method of claim 31 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.
33. **(Withdrawn)** A method of treating a subject with a chemotherapeutic agent wherein said subject harbors a proliferative disorder and neoplastic cells, comprising: (a) administering to the subject an effective amount of a virus under conditions that result in infection of the neoplastic cells by the virus; and (b) administering an effective amount of the chemotherapeutic agent to said subject.
34. **(Withdrawn)** The method of claim 33 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.
35. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate,

hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

36. **(Previously Presented)** The method of claim 27 wherein the reovirus is a mammalian reovirus.
37. **(Previously Presented)** The method of claim 36 wherein the mammalian reovirus is a human reovirus.
38. **(Previously Presented)** The method of claim 37 wherein the human reovirus is a serotype 3 reovirus.
39. **(Previously Presented)** The method of claim 38 wherein the serotype 3 reovirus is a Dearing strain reovirus.
40. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.
41. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered systemically.
42. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is cisplatin.
43. **(Previously Presented)** The method of claim 27 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

44. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.
45. **(Previously Presented)** The method of claim 28 wherein the reovirus is a mammalian reovirus.
46. **(Previously Presented)** The method of claim 45 wherein the mammalian reovirus is a human reovirus.
47. **(Previously Presented)** The method of claim 46 wherein the human reovirus is a serotype 3 reovirus.
48. **(Previously Presented)** The method of claim 47 wherein the serotype 3 reovirus is a Dearing strain reovirus.
49. **(Previously Presented)** The method of claim 28 wherein the reovirus is administered systemically.
50. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is cisplatin.
51. **(Previously Presented)** The method of claim 28 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

52. (New) The method of claim 26, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.
53. (New) The method of claim 26, wherein the reovirus and the chemotherapeutic agent are administered concurrently.
54. (New) The method of claim 27, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.
55. (New) The method of claim 27, wherein the reovirus and the chemotherapeutic agent are administered concurrently.
56. (New) The method of claim 28, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.
57. (New) The method of claim 28, wherein the reovirus and the chemotherapeutic agent are administered concurrently.
58. (New) The method of claim 26, wherein the ras activated neoplasm comprises ras-activated neoplastic cells that are refractory to the chemotherapeutic agent.
59. (New) The method of claim 27, wherein the ras activated neoplasm comprises ras-activated neoplastic cells that are refractory to the chemotherapeutic agent.